Actually just read it and I agree it was disappointing. Default on payments , tiny cash position and high expenses with low revenue. Need to hear some real revenue producing deals . We had the South American one fall through but don’t even know what we got from that . Seems like the other deals are not making the money I would have hoped. Obviously they are forced to partner in Europe as they develop US market .they could still achieve this however with great medical feedback and an insurance reimbursement code . Will listen carefully to the call tomorrow for positive signals. The price is still cheap compared to many other heavy loss making medical device companies
News 
Market Data 
Discover 
